Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
This edition presents key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include the clinical role of MABAs (muscarinic antagonists/beta2 agonists), with GlaxoSmithKline recently initiating Phase II trails with batefenterol, including a combination study with an ICS (fluticasone furoate). KOL’s views of asthma COPD overlap syndrome (ACOS) are explored, including the prospects for GSK’s ICS/LAMA combination that was tested specifically in patients with ACOS. Novartis is developing a “smart” Breezhaler/Neohaler device that electronically captures adherence data: KOLs assess how this novel feature might improve adherence.
Key Questions Answered in this Update Bulletin:
What is the role of MABAs (muscarinic antagonists/beta2 agonists) and what advantages do they offer over current bronchodilators?
What is the rationale for developing MABA/ICS combinations?
Will MABA/ICS provide similar benefits to the more clinically advanced LAMA/LABA/ICS combinations?
Could a MABA be combined with an ICS and an additional anti-inflammatory agent?
Will asthma COPD overlap syndrome (ACOS) be recognized by physicians or regulators as a distinct clinical entity?
Could Novartis’s novel ‘Smart’ Breezhaler/Neohaler device improve adherence?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook